Ionis Pharmaceuticals (NASDAQ: IONS) insider plans 9,884-share sale filing

Rhea-AI Filing Summary

Ionis Pharmaceuticals plans an insider share sale under Rule 144. A holder intends to sell 9,884 shares of Ionis common stock through Morgan Stanley Smith Barney, with an approximate sale date of 01/16/2026 on the NASDAQ. The filing notes that 161,137,930 shares of common stock are outstanding.

The 9,884 shares come from restricted stock units granted on 01/15/2026 under the company’s 2011 Equity Incentive Plan, treated as compensation. Over the prior three months, the same account, using Morgan Stanley Smith Barney as seller, sold 23,463 common shares on 01/02/2026 for gross proceeds of $1,856,324.51. The signer represents they are not aware of any undisclosed material adverse information about Ionis.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	Morgan Stanley Smith Barney 1585 Broadway New York NY 10036	9884	753500.89	161137930	01/16/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	01/15/2026	RSUs granted under 2011 Equity Incentive Plan	Ionis Pharmaceuticals			9884	01/15/2026	Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Morgan Stanley Smith Barney 1585 Broadway New York NY 10036	Common Stock	01/02/2026	23463	1856324.51

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the Form 144 filing for Ionis Pharmaceuticals (IONS) disclose?

The notice discloses an intended sale of 9,884 shares of Ionis Pharmaceuticals common stock under Rule 144, using Morgan Stanley Smith Barney as broker on the NASDAQ.

How many Ionis Pharmaceuticals shares are planned to be sold and when?

The filing indicates an intent to sell 9,884 common shares, with an approximate sale date of 01/16/2026 on the NASDAQ.

How were the Ionis Pharmaceuticals shares in this Form 144 acquired?

The 9,884 shares were obtained as RSUs granted on 01/15/2026 under Ionis Pharmaceuticals’ 2011 Equity Incentive Plan, categorized as compensation.

What prior Ionis Pharmaceuticals share sales are reported in the last 3 months?

The filing reports that 23,463 common shares were sold on 01/02/2026 through Morgan Stanley Smith Barney, generating $1,856,324.51 in gross proceeds.

How many Ionis Pharmaceuticals shares are outstanding in this Form 144?

The document states there are 161,137,930 shares of Ionis Pharmaceuticals common stock outstanding.

What representation does the seller make in the Ionis Pharmaceuticals Form 144?

By signing, the person for whose account the securities are to be sold represents that they do not know any material adverse information about Ionis’ current or prospective operations that has not been publicly disclosed.